Details der Publikation - Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19

Patients will attend up to 9 study visits over a period of up to 28 days..

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	ClinicalTrials.gov - (2021) vom: 30. Nov. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 COVID-19 Medical Condition: COVID-19 Phase: Phase 2 Recruitment Status: Completed Study Type: Interventional

Anmerkungen:	Source: Link to the current ClinicalTrials.gov record., First posted: April 2, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 13, 2021, Last updated: December 15, 2021

Study ID:	NCT04331899 55619
Veröffentlichungen zur Studie:	Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, Purington N, Kamble S, de Vries CR, Quintero O, Feng K, Ley C, Winslow D, Newberry J, Edwards K, Hislop C, Choong I, Maldonado Y, Glenn J, Bhatt A, Blish C, Wang T, Khosla C, Pinsky BA, Desai M, Parsonnet J, Singh U. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021 Mar 30;12(1):1967. doi: 10.1038/s41467-021-22177-1.

fisyears:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG003348512


LEADER	01000caa a22002652 4500
001	CTG003348512
003	DE-627
005	20230426001629.0
007	cr uuu---uuuuu
008	210408s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG003348512
035			\|a (UBBS_Klinische_Studien)NCT04331899
035			\|a (UBBS_Klinische_Studien)55619
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 \|b A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a Source: Link to the current ClinicalTrials.gov record., First posted: April 2, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 13, 2021, Last updated: December 15, 2021
520			\|a Patients will attend up to 9 study visits over a period of up to 28 days.
650		2	\|a COVID-19
650		4	\|a Medical Condition: COVID-19
650		4	\|a Study Type: Interventional
650		4	\|a Recruitment Status: Completed
650		4	\|a Phase: Phase 2
650		4	\|a 610
773	0	8	\|i Enthalten in \|t ClinicalTrials.gov \|g (2021) vom: 30. Nov.
773	1	8	\|g year:2021 \|g day:30 \|g month:11
856	4	0	\|u https://clinicaltrials.gov/show/NCT04331899 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 30 \|c 11